Synapse

← Multiple Sclerosis and Demyelinating Disorders

Papers in Multiple Sclerosis and Demyelinating Disorders

Page 1 · newest first

  1. GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patientsMultiple Sclerosis and Demyelinating Disorders · 2019
  2. Quality of life differences between African Americans and Hispanic Americans with multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2019
  3. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectivesMultiple Sclerosis and Demyelinating Disorders · 2018
  4. Insights on diagnosis and therapeutic decision-making patterns for multiple sclerosis treatment: cross-sectional opinion survey results from Japanese neurologistsMultiple Sclerosis and Demyelinating Disorders · 2018
  5. Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorderMultiple Sclerosis and Demyelinating Disorders · 2018
  6. The role of puberty and adolescence in the pathobiology of pediatric multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2018
  7. Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2018
  8. Differentiating Vogt-Koyanagi-Harada syndrome from recurrent optic neuritis: a case report and review of the literature concerning Hispanic patientsMultiple Sclerosis and Demyelinating Disorders · 2017
  9. The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in ItalyMultiple Sclerosis and Demyelinating Disorders · 2017
  10. Cardiovascular comorbidity in multiple sclerosis patients treated with Mitoxantrone therapy: a cohort studyMultiple Sclerosis and Demyelinating Disorders · 2017
  11. Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2017
  12. May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective studyMultiple Sclerosis and Demyelinating Disorders · 2017
  13. Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?Multiple Sclerosis and Demyelinating Disorders · 2017
  14. Alemtuzumab for multiple sclerosis: the new concept of immunomodulationMultiple Sclerosis and Demyelinating Disorders · 2017
  15. Coincident onset of multiple sclerosis and Herpes simplex virus 1 encephalitis: a case reportMultiple Sclerosis and Demyelinating Disorders · 2017
  16. Pediatric versus adult MS: similar or different?Multiple Sclerosis and Demyelinating Disorders · 2017
  17. Myelin-derived and putative molecular mimic peptides share structural properties in aqueous and membrane-like environmentsMultiple Sclerosis and Demyelinating Disorders · 2017
  18. Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiationMultiple Sclerosis and Demyelinating Disorders · 2017
  19. Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2017
  20. The still under-investigated role of cognitive deficits in PML diagnosisMultiple Sclerosis and Demyelinating Disorders · 2017
  21. Cytokine profiles in pediatric multiple sclerosisView · 2016
  22. Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observationMultiple Sclerosis and Demyelinating Disorders · 2016
  23. Epidemiology of MS in Russia, a historical reviewMultiple Sclerosis and Demyelinating Disorders · 2016
  24. The link of inflammation and neurodegeneration in progressive multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2016
  25. The heritage of glatiramer acetate and its use in multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2016
  26. Antibodies in acquired demyelinating disorders in childrenMultiple Sclerosis and Demyelinating Disorders · 2016
  27. Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2016
  28. Neuroprotective therapies for multiple sclerosis and other demyelinating diseasesMultiple Sclerosis and Demyelinating Disorders · 2016